Method
Level · gp.fundamentals.debt_to_revenue
Raw value 0.00% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTPUMA BIOTECHNOLOGY, INC.'s latest supported as-filed period reports revenue of $56.5M, 7.8% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 0.00% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 2.87% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 7.75% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 23.58% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 77.92% · CORE
Level · gp.fundamentals.operating_margin
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -33.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Debt changed -100.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Inventory changed +55.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
PBYI · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001437749-26-026311SEC ↗8-KAug 6, 2026Period Aug 6, 20260001437749-26-026282SEC ↗4Jul 8, 2026Period Jul 6, 20260001437749-26-023079SEC ↗4Jul 8, 2026Period Jul 6, 20260001437749-26-023078SEC ↗4Jul 8, 2026Period Jul 6, 20260001437749-26-023077SEC ↗8-KJun 16, 2026Period Jun 11, 20260001437749-26-020793SEC ↗4Jun 15, 2026Period Jun 11, 20260001437749-26-020709SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 6, 2026Filed Jul 8, 2026 | AUERBACH ALAN HPresident and CEO | Open Market SaleDirect | 44,058 | $8 | $364,051 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 13.42% · CORE
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 3.46% · OPTIONAL
Net income changed +39.9% from the comparable as-filed period.
Operating income changed +14.3% from the comparable as-filed period.
Operating margin changed +77 basis points from the comparable as-filed period.
Revenue changed +7.8% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001437749-26-020708